Activity of a trinuclear platinum complex in human ovarian cancer cell lines sensitive and resistant to cisplatin: cytotoxicity and induction and gene-specific repair of DNA lesions
2001
Effect of a New Platinum Drug on Ovarian Cancer Cells
publication
Author Information
Author(s): Colella G, Pennati M, Bearzatto A, Leone R, Colangelo D, Manzotti C, Daidone M G, Zaffaroni N
Primary Institution: Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori
Hypothesis
How does a trinuclear platinum complex affect ovarian cancer cells that are sensitive and resistant to cisplatin?
Conclusion
The trinuclear platinum complex BBR 3464 shows collateral sensitivity in some ovarian cancer cell lines resistant to cisplatin.
Supporting Evidence
- BBR 3464 showed collateral sensitivity in two ovarian cancer cell lines resistant to cisplatin.
- Loss of mismatch repair proteins did not affect sensitivity to BBR 3464.
- Differences in DNA lesion repair kinetics were observed between BBR 3464 and cisplatin.
Takeaway
A new drug called BBR 3464 might work better than cisplatin for some ovarian cancer cells that don't respond to cisplatin anymore.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website